Refine by
Diabetic Control Articles & Analysis
21 news found
Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us." ...
Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us." ...
This year's certified measures include Hemoglobin A1c Control for Patients with Diabetes (HBD), Blood Pressure Control for Patients with Diabetes (BPD), Kidney Health Evaluation for Patients with Diabetes (KED), Lead Screening in Children (LSC), and Child and Adolescent Well-Care Visits (WCV). ...
Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us." ...
An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM). ...
Schmid brings extensive operations and business development leadership experience in diabetes and drug delivery. As Vice President of Operations and Business Development at Insulet Corporation, he was instrumental in the development, manufacturing, and commercialization of wearable smart drug delivery pumps such as the Omnipod Diabetes Management System, the ...
The data was presented by Robert Ryder, M.D. of City Hospital, Birmingham, U.K. at the 82nd Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans on June 6, 2022. Both studies demonstrate the safety and efficacy profile that EndoBarrier provides patients diagnosed with type 2 diabetes and/or obesity. “In these analyses, the ...
Results from a Multicenter Randomized Sham-controlled Trial of a Duodenal Jejunal Bypass Liner for the Treatment of Type 2 Diabetes Mellitus were presented by Christopher C. ...
In a randomized, double-blind, placebo-controlled Phase 1b trial treating patients with chronic moderate to severe diabetic foot ulcer infection, topical pravibismane treatment plus standard of care demonstrated a numeric 85% wound size reduction versus 30% placebo plus standard of care. ...
Our mission is to improve access to the highest standards of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us." ...
Abstract and publication #92-OR entitled “Persistence of Impaired Awareness of Hypoglycemia, Severe Hypoglycemic Events and Suboptimal Glycemic Control Despite Advanced Diabetes Technologies,” to be presented Saturday, June 4, 2022 at 1:45 p.m. ...
Five mice not treated with STZ were used as a non-diabetic control. At the end of treatment, urinary albumin to creatinine ratio (ACR), renal matrix remodeling, glomerular filtration and interstitial fibrosis were assessed in addition to glucose levels, body weight, and organ weights. About Diabetic Nephropathy Diabetic ...
The Phase II clinical trial is conducted in the form of randomized, multi-blind, multi-center placebo-controlled trial, exploring the efficacy and safety of RGT-075 in patients with type 2 diabetes mellitus who have poor glycemic control following metformin treatment. ...
The publication, “Durable Metabolic Improvements 2 Years After Duodenal Mucosal Resurfacing (DMR) in Patients with Type 2 Diabetes (REVITA-1 Study),” appeared in the January 12, 2022, online issue of Diabetes Research and Clinical Practice. With two-year follow-up from 34 patients in the per-protocol (PP) population, the study observed no long-term ...
BOSTON & HYDERABAD, India--( )-- GI Dynamics Inc., a medical device company that isBUSINESS WIRE developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, is pleased to announce that it has received regulatory approval to begin enrollment in the I-STEP clinical trial in India. I-STEP is a multi-center, randomized, pivotal study ...
Semglee® is indicated to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. ...
ByBiocon
(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the results from data presentations at NANS supporting the use of HF10® therapy for patients with chronic pain, including results from the Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) ...
Revita® DMR is the first and only procedural therapy for type 2 diabetes; Revita DMR has been shown to durably improve blood sugar control without the need for escalating drug therapy and to reduce liver fat in NAFLD/NASH in clinical studies to date. ...
” Gastroparesis It is estimated that there are 5.8 million patients with suspected gastroparesis in the United States. The most common forms are diabetic, idiopathic and post-surgical gastroparesis, which is sometimes associated with vagotomy and vagus nerve injury. Some pharmacologic agents, especially narcotic opiate analgesics, anticholinergic agents and some ...
Researchers at the University of Arizona College of Pharmacy have discovered that nonalcoholic steatohepatitis (NASH), an increasingly common but often undiagnosed liver disease, could have significant medical implications for people with type 2 diabetes. People develop NASH when early liver disease, characterized by too much fat in the liver, is exacerbated by inflammation. ...